No. NAD+ is a dinucleotide coenzyme, not a peptide. It consists of two nucleotide units—one carrying nicotinamide and one carrying adenine—connected through phosphate groups. Peptides are chains of amino acids connected by peptide bonds, so the two molecules have different building blocks and chemical backbones.

Why do clinics call NAD+ a peptide?

Because NAD+ is often listed, prescribed, compounded, and injected alongside peptide therapies. That shared setting makes the category shorthand tempting, but route and packaging do not determine chemical class. NAD+ remains a nucleotide-based coenzyme even when it comes in a vial on the same menu as peptides.

What does NAD+ do in the body?

NAD+ acts both as a redox cofactor and as a substrate for signaling enzymes. The NAD+/NADH pair transfers electrons through metabolic pathways tied to mitochondrial energy production. Sirtuins and PARPs also consume NAD+ during protein regulation and DNA-damage responses. Those essential roles do not by themselves prove a clinical outcome from administering NAD+.

Do NAD+ levels decline with age?

They have declined with age in specific human tissue studies, but the pattern should not be treated as universal. One cross-sectional study of 49 human pelvic-skin samples found negative correlations between age and NAD+ in both sexes. That association does not establish one cause or show that raising a blood measurement changes an aging outcome.

Is an NAD+ injection the same as taking NMN or NR?

No. An NAD+ injection contains NAD+ itself, while oral NMN and NR are precursors the body must absorb and convert through NAD+ synthesis pathways. Human studies also used different routes, populations, and endpoints, so results from an NMN or NR trial cannot be assumed to describe an NAD+ injection.

Is NAD a Peptide? What NAD+ Actually Is

No—NAD+ is a coenzyme called nicotinamide adenine dinucleotide, not a peptide. The question "is NAD a peptide?" is understandable because clinics often list NAD+ beside peptide therapies and may offer both by injection. Chemically, though, they belong to different categories. NAD+ is two nucleotides—one carrying nicotinamide and one carrying adenine—linked through phosphate groups. A peptide is a chain of amino acids joined by peptide bonds.

That distinction tells us what the molecule is. It does not tell us whether a particular route has strong clinical evidence, which is a separate question.

Is NAD a peptide? The chemistry decides

The name contains the answer: the "D" in NAD stands for dinucleotide. Each of its two nucleotide units includes a ribose sugar and phosphate. One carries nicotinamide; the other carries adenine. The phosphate groups connect the two units. There is no amino-acid chain or peptide-bond backbone.

Feature	NAD+	Peptide
Main building units	Two nucleotides	Amino acids
Connection	Phosphate linkage	Peptide bonds
Chemical class	Dinucleotide coenzyme	Amino-acid chain
Familiar partner	NADH, its reduced form	Varies by peptide

The plus sign also has a precise meaning. NAD+ is the oxidized member of the NAD+/NADH pair. It does not mean a stronger version of NAD, and it does not make the molecule a peptide.

Why NAD+ gets called a peptide

The confusion comes from context rather than chemistry. NAD+ appears on the same clinic menus as peptides, may be prepared by the same compounding pharmacy, and can arrive in a vial for injection. People understandably use the category name for the whole menu.

Route and packaging do not determine molecular class. Insulin is a peptide whether it is in a vial or pen. NAD+ remains a nucleotide-based coenzyme whether discussed inside a cell, in a capsule claim, or in an injectable preparation.

What NAD+ actually does

NAD+ has two broad cellular jobs. First, it is a redox cofactor. It accepts electrons in metabolic reactions to become NADH, and NADH can pass those electrons onward. This cycling helps connect the breakdown of nutrients to mitochondrial energy production. A biochemical review describes NAD as a cofactor used by hundreds of enzymes in redox reactions.

Second, NAD+ is a consumable substrate for signaling enzymes. Sirtuins use it during protein deacylation. PARPs use it to add ADP-ribose units to proteins, including during responses to DNA damage. A 2019 review in Antioxidants & Redox Signaling separates these redox and nonredox roles.

Those jobs explain why NAD+ attracts interest in metabolism and aging. They do not show that administering more NAD+ improves energy, fatigue, cognition, or longevity. A molecule can be essential to cell biology while the best way to alter its level—and the clinical value of doing so—remains unsettled.

Why NAD+ levels can fall with age

The strongest wording is that NAD+ has declined with age in some measured human tissues, not that every tissue follows one fixed curve. In a 2012 study of 49 human pelvic-skin samples, tissue NAD+ correlated negatively with age in males (r = -0.706) and females (r = -0.537). DNA damage also rose with age in both groups. PARP activity increased with age in males and was inversely related to NAD+; the patterns were less clear in females. The human tissue study was cross-sectional, so it shows association rather than proving one cause.

Researchers are studying both sides of the balance: cells may make or recycle less NAD+, consume more of it through enzymes such as PARPs, or do both. The mix can differ by tissue, health, and activity. Most importantly, observing lower levels with age does not establish that raising a blood measurement will change an age-related outcome.

NAD+ injection versus NMN and NR

An NAD+ injection starts with NAD+ itself outside cells. NMN, or nicotinamide mononucleotide, and NR, or nicotinamide riboside, are precursors: the body must absorb and convert them through NAD+ synthesis pathways. That makes them related, but not interchangeable.

The direct-administration evidence is small. In a 2019 pilot, eight men received 750 mg of NAD+ intravenously over six hours and three received saline. Infused NAD+ was rapidly removed from plasma for at least the first two hours, while related metabolites changed. The study measured pharmacokinetics, not symptom improvement, and its intravenous findings should not be treated as evidence for every injectable route. The broader NAD+ injections overview covers routes and the clinical process; NAD+ injection side effects owns the tolerability question.

Oral precursor trials ask different questions:

NMN: A 2021 randomized trial studied 250 mg daily for 10 weeks in 25 postmenopausal women with overweight or obesity and prediabetes. Muscle insulin sensitivity increased by about 25%, while body composition, fasting glucose, and liver insulin sensitivity did not change. The Science trial does not establish the same result in men, younger adults, or people without prediabetes.
NR: A 2018 crossover trial studied 500 mg twice daily for six weeks in healthy middle-aged and older adults. NAD+ in peripheral blood mononuclear cells rose by about 60% versus placebo among 21 participants with analyzable samples. The Nature Communications trial established bioavailability in that setting, not a general anti-aging outcome.

These studies involve different molecules, routes, populations, and endpoints. Their numbers cannot be lined up as a contest between injection, NMN, and NR.

What prescription status means

As of August 2026, NAD+ is not FDA-approved as an injectable therapy. A February 2026 FDA warning letter specifically described a repackaged NAD+ 50 mg/mL injection as an unapproved new drug. At Promise, NAD+ is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

FDA status is one fact in clinical review, not a marketing gate. A licensed provider may still prescribe a compounded formulation when clinically appropriate, and that decision is between the patient and provider. At Promise, a licensed provider reviews every request and either prescribes or declines based on medical eligibility; not everyone qualifies.

The useful distinction

Calling NAD+ a coenzyme keeps the biology honest. It separates what NAD+ does inside cells from what any therapy has demonstrated in people. It also makes comparisons cleaner: injection supplies NAD+ itself, while NMN and NR supply precursors used to build it.

Promise's NAD+ product sits within its broader energy and focus options, but the menu does not change the molecule. NAD+ is a dinucleotide coenzyme that happens to be prescribed alongside peptides. It is not one of them.